In the PRIMA trial, Zejula (niraparib) improved progression-free survival when used as a maintenance ... Moreover, despite high response rates to platinum-based chemotherapy in the second-line ...
The FDA has approved GlaxoSmithKline’s Zejula (niraparib ... to Lynparza results in improved progression-free survival in a wider group of patients with advanced ovarian, fallopian tube ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback